ALM201, like other FKBPL derivatives, inhibits breast cancer metastasis through Notch signalling, showing excellent safety profile in Phase 1 clinical trials, when applied for the treatment of ovarian cancer and solid tumor (McClements et al., 2019). Here, FKBPL is linked to breast carcinoma.